 |
|
Alloantigen Gene Therapy for Squamous Cell Carcinoma of the Head and Neck
Results of a Phase 1 Trial
Lyon L. Gleich, MD;
Jack L. Gluckman, MD;
Shanna Armstrong, RN;
Paul W. Biddinger, MD;
Mary Ann Miller, BS;
Kamala Balakrishnan, MD;
Keith M. Wilson, MD;
Harold I. Saavedra, PhD;
Peter J. Stambrook, PhD
Arch Otolaryngol Head Neck Surg. 1998;124:1097-1104.
Objective To determine the safety and efficacy of an immunogenic gene therapy using a drug designed to produce expression of a foreign class I major histocompatibility complex protein in patients with head and neck cancer.
Design Phase 1 prospective clinical trial.
Setting Academic medical setting.
Patients Nine patients with advanced head and neck squamous cell carcinoma who had failed conventional therapy and did not express HLA-B7, a class I major histocompatibility complex protein.
Intervention Patients were treated with Allovectin-7 (Vical Inc, San Diego, Calif) by direct intratumoral injection. Allovectin-7 contains a plasmid complementary DNA complexed with a cationic lipid, which results in expression of HLA-B7.
Main Outcome Measures Patients were assessed for any toxic effects and for any change in tumor volume. Biopsy specimens obtained before and after therapy were evaluated by immunohistochemistry to detect HLA-B7 expression and with the terminal deoxynucleotide transferase–mediated deoxyuridine triphosphate–biotin nick end labeling (TUNEL) assay to detect any induction of apoptosis.
Results There were no toxic effects of the gene therapy. In 4 of these 9 patients there was a partial response to treatment, evidenced by a gradual reduction in tumor size. One patient has remained alive for more than 17 months since commencing treatment, with no clinical evidence of disease but with persistent histological evidence of cancer. Analysis of the biopsy specimens from 2 of the patients who responded to therapy demonstrated HLA-B7 expression. The TUNEL assay demonstrated extensive apoptosis in both of these patients, suggesting that this may be the mechanism of tumor reduction.
Conclusions These data demonstrate the potential efficacy and lack of toxicity of this form of alloantigen gene therapy. A multi-institutional study has been initiated to expand on these findings.
From the Departments of Otolaryngology (Drs Gleich, Gluckman, and Wilson and Ms Armstrong), Pathology and Laboratory Medicine (Drs Biddinger and Balakrishnan and Ms Miller), and Cell Biology, Neurobiology, and Anatomy (Drs Saavedra and Stambrook), University of Cincinnati Medical Center, Cincinnati, Ohio.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Allogeneic MHC Gene Transfer Enhances an Effective Antitumor Immunity in the Early Period of Autologous Hematopoietic Stem Cell Transplantation
Kobayashi et al.
Clin. Cancer Res. 2007;13:7469-7479.
ABSTRACT
| FULL TEXT
Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi et al.
Clin. Cancer Res. 2006;12:2208-2215.
ABSTRACT
| FULL TEXT
Endocrine Aspects of Cancer Gene Therapy
Barzon et al.
Endocr. Rev. 2004;25:1-44.
ABSTRACT
| FULL TEXT
Clinical Experience With HLA-B7 Plasmid DNA/Lipid Complex in Advanced Squamous Cell Carcinoma of the Head and Neck
Gleich et al.
Arch Otolaryngol Head Neck Surg 2001;127:775-779.
ABSTRACT
| FULL TEXT
THE IMPACT OF TISSUE ENGINEERING ON DENTISTRY
BAUM and MOONEY
Journal of the American Dental Association 2000;131:309-318.
ABSTRACT
| FULL TEXT
The Evolving Role of Combined Modality Therapy in Head and Neck Cancer
Robbins
Arch Otolaryngol Head Neck Surg 2000;126:265-269.
FULL TEXT
|
